Lytix Biopharma ASA - Mandatory notification of trade by close associates to primary insiders
Oslo, Norway, 18 November 2026: Reference is made to the stock exchange announcement published by Lytix Biopharma ASA ("Lytix" or the "Company") today regarding the private placement and retail offering (the "Offerings") for a total of 10,000,000 new shares (the "Offer Shares") to be issued by the Company at an offer price of NOK 8.00 per Offer Share (the "Offer Price"). The new shares will be issued pursuant to a board authorisation granted by the Company's extraordinary general meeting on 26 January 2026 (the "Board Authorisation").
The following close associates to a primary insider in the Company will receive Offer Shares as follows: - Saturn Invest AS, a close associate to primary insider Brynjar Forbergskog (board member), has been allocated, and will subscribe for 2,661,535 Offer Shares at the Offer Price; - HIFO Invest AS, a close associate to primary insider Brynjar Forbergskog (board member), has been allocated, and will subscribe for 625,000 Offer Shares at the Offer Price; - Øystein Rekdal, CEO and primary insider, has been allocated, and will acquire 12,500 Offer Shares at the Offer Price; - Gjest Breistein, CFO and primary insider, has been allocated, and will acquire 12,500 Offer Shares at the Offer Price; and - Baldur Sveinbjørnsson, CSO and primary insider, has been allocated, and will acquire 6,250 Offer Shares at the Offer Price.
Further, Saturn Invest AS, a close associate to board member Brynjar Forbergskog, has lent a total of 1,118,247 existing shares in the Company to DNB Carnegie, a part of DNB Bank ASA, in its capacity as manager (the "Manager"), pursuant to a share lending agreement entered into between the Company, the Manager, Saturn Invest AS and other share lenders, in order to facilitate delivery-versus-payment settlement of the Offer Shares allocated to investors in the share issue (including the retail offering), excluding Offer Shares allocated to the share lenders. The share loan will be settled with new shares in the Company to be issued by the board of directors pursuant to the Board Authorisation. During the term of the share loan, and prior to redelivery, Saturn Invest AS' shareholding in the Company will be reduced from 6,707,801 shares to 5,589,554 shares.
Please see the attached forms for further details about the transactions.
Disclosure regulation: This information is subject to the disclosure requirements pursuant to article 19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian Securities Trading Act.
For more information, please contact: Gjest Breistein, CFO gjest.breistein@lytixbiopharma.com +47 952 60 512
About Lytix Biopharma: Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly differentiated oncolytic molecule platform based on world-leading research in host-defense peptide-derived molecules. Lytix Biopharma's lead product, ruxotemitide (formerly LTX-315), is a first-in-class oncolytic molecule representing a new approach to effectively prime durable anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that work across multiple cancer indications and treatment settings, both as monotherapy and in combination therapy. Lytix Biopharma is listed on Euronext Growth Oslo under the ticker LYTIX.